Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (vol 389, pg 67, 2017)

被引：0
|
作者：
Balar, A., V
Galsky, M. D.
Rosenberg, J. E.
机构：
来源：
LANCET | 2017年 / 390卷 / 10097期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：848 / 848
页数：1
相关论文
共 50 条
  • [21] Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
    Santoni, Matteo
    Myint, Zin W.
    Buettner, Thomas
    Takeshita, Hideki
    Okada, Yohei
    Lam, Elaine T.
    Gilbert, Danielle
    Kueronya, Zsofia
    Tural, Deniz
    Pichler, Renate
    Grande, Enrique
    Crabb, Simon J.
    Kemp, Robert
    Massari, Francesco
    Scagliarini, Sarah
    Iacovelli, Roberto
    Vau, Nuno
    Basso, Umberto
    Maruzzo, Marco
    Molina-Cerrillo, Javier
    Galli, Luca
    Bamias, Aristotelis
    De Giorgi, Ugo
    Zucali, Paolo Andrea
    Rizzo, Mimma
    Seront, Emmanuel
    Popovic, Lazar
    Caffo, Orazio
    Buti, Sebastiano
    Kanesvaran, Ravindran
    Kopecky, Jindrich
    Kucharz, Jakub
    Zeppellini, Annalisa
    Fiala, Ondrej
    Landmesser, Johannes
    Ansari, Jawaher
    Giannatempo, Patrizia
    Rizzo, Alessandro
    Zabalza, Ignacio Ortego
    Monteiro, Fernando Sabino M.
    Battelli, Nicola
    Calabro, Fabio
    Porta, Camillo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 2961 - 2970
  • [22] IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
    Bellmunt, J.
    Balar, A.
    Galsky, M. D.
    Loriot, Y.
    Theodore, C.
    Grande Pulido, E.
    Castellano, D.
    Retz, M.
    Niegisch, G.
    Bracarda, S.
    Necchi, A.
    Vaishampayan, U.
    Sridhar, S.
    Eigl, B. J.
    Hussain, S.
    van der Heijden, M.
    Danner, B.
    Mariathasan, S.
    Legrand, F.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
    Matteo Santoni
    Zin W. Myint
    Thomas Büttner
    Hideki Takeshita
    Yohei Okada
    Elaine T. Lam
    Danielle Gilbert
    Zsófia Küronya
    Deniz Tural
    Renate Pichler
    Enrique Grande
    Simon J. Crabb
    Robert Kemp
    Francesco Massari
    Sarah Scagliarini
    Roberto Iacovelli
    Nuno Vau
    Umberto Basso
    Marco Maruzzo
    Javier Molina-Cerrillo
    Luca Galli
    Aristotelis Bamias
    Ugo De Giorgi
    Paolo Andrea Zucali
    Mimma Rizzo
    Emmanuel Seront
    Lazar Popovic
    Orazio Caffo
    Sebastiano Buti
    Ravindran Kanesvaran
    Jindrich Kopecky
    Jakub Kucharz
    Annalisa Zeppellini
    Ondřej Fiala
    Johannes Landmesser
    Jawaher Ansari
    Patrizia Giannatempo
    Alessandro Rizzo
    Ignacio Ortego Zabalza
    Fernando Sabino M. Monteiro
    Nicola Battelli
    Fabio Calabrò
    Camillo Porta
    Cancer Immunology, Immunotherapy, 2023, 72 : 2961 - 2970
  • [24] SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma
    Geldart, Thomas
    Chester, John
    Casbard, Angela
    Crabb, Simon
    Elliott, Tony
    Protheroe, Andrew
    Huddart, Robert A.
    Mead, Graham
    Barber, Jim
    Jones, Robert J.
    Smith, Joanna
    Cowles, Robert
    Evans, Jessica
    Griffiths, Gareth
    EUROPEAN UROLOGY, 2015, 67 (04) : 599 - 602
  • [25] Atezolizumab for Cisplatin-Inappropriate Patients with advanced or metastatic Urothelial Carcinoma Results of single-arm Phase-II-Study (IMvigor 210)
    Wezel, Felix
    Bolenz, Christian
    ONKOLOGE, 2017, 23 (10): : 858 - 860
  • [26] Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma
    Gartrell, Benjamin Adam
    Hahn, Noah M.
    Hutson, Thomas E.
    Sonpavde, Guru
    Hauke, Ralph J.
    Starodub, Alexander
    Small, Alexander C.
    Tsao, Che-Kai
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.
    Lai, Yizhen
    Zhong, Yichen
    Li, Haojie
    Patterson, Karl
    Hale, Oliver
    Meng, Yang
    Frenkl, Tara L.
    Godwin, James Luke
    Mamtani, Ronac
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [28] A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
    Schuetze, Scott M.
    Ballman, Karla V.
    Heise, Rachel
    Ganjoo, Kristen N.
    Davis, Elizabeth J.
    George, Suzanne
    Burgess, Melissa A.
    Choy, Edwin
    Shepard, Dale R.
    Tinoco, Gabriel
    Kelly, Ciara M.
    Hirbe, Angela
    Attia, Steven
    Deshpande, Hari A.
    Schwartz, Gary K.
    Siontis, Brittany L.
    Riedel, Richard F.
    von Mehren, Margaret
    Kozlowski, Erin
    Chen, Helen X.
    Astbury, Caroline
    Rubin, Brian P.
    CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4584 - 4592
  • [29] Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma
    Urakami, Shinji
    Fujii, Yasuhisa
    Yamamoto, Shinya
    Yuasa, Takeshi
    Kitsukawa, Shinichi
    Sakura, Mizuaki
    Yano, Akihiro
    Saito, Kazutaka
    Masuda, Hitoshi
    Yonese, Junji
    Fukui, Iwao
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 35.e1 - 35.e7
  • [30] Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial
    Xiao, Zhehao
    Chen, Weiling
    Du, Youqin
    Zeng, Fanyan
    Su, Fang
    Huang, Shiting
    Qu, Song
    INTERNATIONAL JOURNAL OF CANCER, 2025,
12345